What is Cosentyx?
Cosentyx (secukinumab) is an injectable biologic drug that targets interleukin-17A (IL-17A), a protein involved in inflammation. Approved by the FDA in 2015, it treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa in adults and children.[1]
How does Cosentyx work?
It binds to IL-17A, blocking its interaction with receptors on cells, which reduces inflammation in autoimmune conditions like psoriasis and arthritis. Administered via subcutaneous injection, typically starting with loading doses followed by weekly or monthly maintenance.[1]
What conditions does Cosentyx treat?
- Moderate to severe plaque psoriasis (ages 6+)
- Active psoriatic arthritis
- Active ankylosing spondylitis
- Active non-radiographic axial spondyloarthritis
- Moderate to severe hidradenitis suppurativa (adults)
It's not approved for rheumatoid arthritis or osteoarthritis.[1]
Common side effects and risks
Patients report upper respiratory infections, diarrhea, and injection-site reactions. Serious risks include infections (e.g., tuberculosis reactivation), inflammatory bowel disease flares, and hypersensitivity. Monitoring for infections is required before starting.[1]
Who makes Cosentyx and how much does it cost?
Novartis manufactures and markets it. List price is around $6,000-$7,000 per month without insurance, though patient assistance programs and copay cards can lower costs.[1]
When does Cosentyx patent expire?
Key U.S. patents on secukinumab expire in 2026-2032, with formulation patents extending to 2036. Challenges from biosimilar developers like Alvotech and Formycon are ongoing.2
How does Cosentyx compare to other biologics?
| Drug | Target | Key Conditions | Dosing Frequency |
|------|--------|----------------|------------------|
| Cosentyx (secukinumab) | IL-17A | Psoriasis, PsA, AS | Monthly after loading |
| Stelara (ustekinumab) | IL-12/23 | Psoriasis, PsA, Crohn's | Every 8-12 weeks |
| Tremfya (guselkumab) | IL-23 | Psoriasis, PsA | Every 8 weeks |
| Skyrizi (risankizumab) | IL-23 | Psoriasis, PsA, Crohn's | Every 12 weeks |
Cosentyx shows similar efficacy to IL-23 inhibitors in psoriasis but may have higher infection rates.[1]
[1]: https://www.cosentyx.com